Lyka Labs (BOM:500259) Cyclically Adjusted PB Ratio: (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500259 Lyka Labs Ltd BOM:500259
51 GF Score
Price ₹77.52
GF Value ₹129.55
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lyka Labs Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lyka Labs  (BOM:500259) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lyka Labs Cyclically Adjusted PB Ratio Related Terms


Lyka Labs Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Lyka Labs's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyka Labs Cyclically Adjusted PB Ratio Chart

Lyka Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.79 5.25 5.10 2.38

Lyka Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.95 0.00 2.38 0.00

BOM:500259 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Lyka Labs's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Cyclically Adjusted PB Ratio falls into.


BOM:500259
51GF Score
Lyka Labs Ltd BOM:500259
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyka Labs Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lyka Labs's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lyka Labs's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Lyka Labs Quarterly Data

Book Value per Share CPI Adj_Book
201512 25.933 102.901 42.177
201603 20.527 102.518 33.510
201606 0.000 105.961 0.000
201609 18.425 105.961 29.101
201612 0.000 105.196 0.000
201703 17.110 105.196 27.220
201803 17.579 109.786 26.797
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 15.286 118.202 21.643
201906 0.000 120.880 0.000
201909 13.944 123.175 18.946
201912 0.000 126.235 0.000
202003 -5.000 124.705 -6.710
202006 0.000 127.000 0.000
202009 -8.669 130.118 -11.150
202012 0.000 130.889 0.000
202103 -8.992 131.771 -11.420
202106 0.000 134.084 0.000
202109 7.689 135.847 9.472
202112 0.000 138.161 0.000
202203 4.649 138.822 5.605
202206 0.000 142.347 0.000
202209 4.701 144.661 5.439
202212 0.000 145.763 0.000
202303 14.806 146.865 16.872
202306 0.000 150.280 0.000
202309 20.616 151.492 22.775
202312 0.000 152.924 0.000
202403 20.597 153.035 22.525
202406 0.000 155.789 0.000
202409 27.714 157.882 29.377
202412 0.000 158.323 0.000
202503 29.014 157.552 30.820
202506 0.000 159.755 0.000
202509 28.334 162.289 29.219
202512 0.000 163.281 0.000
202603 25.888 164.272 26.374
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹77.52 is trading 40.2% below its estimated GF Value™ of ₹129.55. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹129.55 vs. price of ₹77.52 (40.2% below fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
51GF Score

Get the complete analysis for BOM:500259

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹77.52
Price
₹129.55
GF Value